Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma 725Lymphoma, Non-Hodgkin 659Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Leukemia, Lymphocytic, Chronic, B-Cell 555Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 418Lymphoma, Mantle-Cell 345Burkitt Lymphoma 306Leukemia 304Leukemia, Myeloid, Acute 298Hodgkin Disease 294Lymphoma, B-Cell 281Lymphoma, B-Cell, Marginal Zone 267Recurrence 246Multiple Myeloma 205Neoplasms 200Myelodysplastic Syndromes 171Lymphoma, T-Cell, Cutaneous 171Lymphoma, Large-Cell, Immunoblastic 160Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 159Waldenstrom Macroglobulinemia 146Lymphoma, Large-Cell, Anaplastic 142Mycosis Fungoides 132Sezary Syndrome 119Immunoblastic Lymphadenopathy 108Blast Crisis 92Hematologic Neoplasms 91Lymphoma, T-Cell, Peripheral 86Leukemia, Myelogenous, Chronic, BCR-ABL Positive 86Lymphoma, T-Cell 82

Interventions

urelumab 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × B-Cell Malignancies × Lymphoid × Clear all
NCT05683717 2023-11-21

A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

TransThera Sciences (Nanjing), Inc.

Phase 1 Recruiting
37 enrolled
Lymphoid

B-Cell Malignancies

NCT05275504 2022-06-09

Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

TransThera Sciences (Nanjing), Inc.

Phase 1 Unknown
37 enrolled
Lymphoid

B-Cell Malignancies

NCT01775631 2017-03-31

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma

Bristol-Myers Squibb

Phase 1 Completed
47 enrolled
Lymphoid

B-Cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡